10 June 2020
Our latest release: MERCURY™ v3.0
We are excited to provide you with important information regarding the release of a new version (v3.0) of MERCURY™. This updated version of MERCURY has a number of changes and improvements designed to enhance data analysis capabilities and the user experience.
MERCURY v3.0 has (…) »
13 April 2020
IntegraGen announces the company’s MERCURY™ cloud-based analytical software tool has achieved Conformité Européenne (CE) marking. This registration enhances the ability for IntegraGen sell MERCURY throughout the European Union (EU). MERCURY is utilized by researchers and clinicians to assist with the analysis of sequencing data derived from small (…) »
31 March 2020
IntegraGen is following the French Government’s recommendations and precautionary measures for COVID-19. As an essential supplier of genomic research services, we are committed to meeting the needs of our customers while also making every effort to protect the health and well-being of our employees and their families.
We have undertaken (…) »
17 March 2020
Dear IntegraGen partner and customer,
We value your well-being and understand that the entire community is impacted by the novel coronavirus (COVID-19) outbreak. This is why we are committed to providing consistent and timely support so your important work is not interrupted.
IntegraGen is closely monitoring guidance from health authorities (…) »
21 October 2018
Analysis of PETACC-8 clinical trial samples demonstrates company’s proprietary miR-31 microRNA biomarkers identifies subpopulations of patients with resected stage III colon cancer who benefit from the addition of cetuximab to FOLFOX adjuvant therapy
IntegraGen announced today that it presented data on the company’s proprietary miR-31 (…) »
19 September 2018
IntegraGen has been nominated for a 2018 PrixGalien MedStartup Award, a joint initiative between The Galien Foundation and Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry. IntegraGen was selected as a nominee by an (…) »
06 September 2018
GoPath Laboratories, IntegraGen’s North American licensing partner for the company’s miR-31-3p test, announced that the American Medical Association (AMA) has assigned a new, discreet CPT (Current Procedural Technology) code to facilitate reimbursement of miR-31now®, a proprietary miRNA-based molecular test which predicts the potential clinical benefits associated with (…) »
01 June 2018
GoPath Laboratories, IntegraGen’s licensing partner in the U.S., has announced that it will launch a propriety new test, miR-31now™ during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago. The miR-31now test is the first positive theranostic test for patients with (…) »
25 May 2018
IntegraGen will be in attendance at 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago from June 1st to June 5th. The Annual ASCO Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new (…) »
17 March 2018
IntegraGen is pleased to announce that a comprehensive summary of the results of validation studies associated with the company’s proprietary miR-31-3p expression test has been published online in Biomarker Insights following peer-review.
The paper entitled “Technical validation of a reverse-transcription quantitative polymerase chain reaction in vitro (…) »